Novo Refuses to Give Up on Insulin Icodec, Eyes Combo Filing With Semaglutide

By the end of the year, Novo Nordisk intends to make a regulatory filing for the combination of its icodec and semaglutide, keeping its once-weekly insulin program afloat.

Read more about this post on Biospace